Severe ovarian hyperstimulation syndrome and deep venous thrombosis.
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
A Tiitinen
Publications and source records attributed to A Tiitinen.
Placental protein 10 (PP10) in singleton and twin pregnancy complicated by pre-eclampsia.
Circulating levels of placental protein 10 (PP10) were measured by radioimmunoassay in 140 women with normal singleton pregnancy (140 samples), in 6 women with normal twin pregnancy (15 samples) and in 35 pregnant women with pre-eclampsia (51 samples from singleton pregnancies and 7 samples from twin pregnancies) between 24 and 40 weeks. In singleton pregnancies with pre-eclampsia, the levels were lower than normal (P less than 0.01). In twin pregnancy the circulating PP10 levels were not significantly affected. These results suggest that changes in placental function are reflected in the circulating PP10 levels.
Female↗
Placental protein 10 (PP10) in the serum of patients with trophoblastic and nontrophoblastic gynaecological tumours.
Serum levels of placental protein 10 (PP10) were measured by radioimmunoassay in patients with trophoblastic (n = 23) and non-trophoblastic (n = 122) gynaecological tumours before, during and after treatment. Elevated levels (greater than 2.0 micrograms/l) were found in 96% of patients with an untreated trophoblastic tumour, and in 22%, 20% and 12% of patients with endometrial, cervical and ovarian carcinoma, respectively. After treatment the levels fell in patients with trophoblastic disease. Although PP10 may be tumour-associated in such cases, it is premature to assume any significance for PP10 as a tumour marker in clinical practice, because changes in serum hCG levels are much more informative.
Female↗
Human endometrium and menstrual fluid contain placental protein 10 (PP10).
Placental protein 10 (PP10), a newly isolated protein from the human placenta, was detected by radioimmunoassay in 10 out of 23 extracts of proliferative and secretory endometrium and in all of the 20 menstrual fluids examined. The concentrations were higher in the secretory phase, when the tissue PP10 content ranged from less than 0.2 to 1.3 microgram/g of endometrial cytosol protein. In menstrual fluid, PP10 was found at concentrations of 16 to 270 micrograms/l. In RIA, the dose-response curves of endometrial, menstrual fluid and purified PP10 were parallel. In gel filtration, the major part of PP10 from the endometrium and menstrual fluid eluted in the same fraction as purified placental PP10. Our results add another placental protein to the list of placental proteins which also appear in the endometrium.
Adult↗
Placental protein 10: levels in benign and malignant ovarian cyst fluids and pleural exudates.
Placental protein 10 (PP10) was measured in benign (n = 47) and malignant (n = 10) ovarian cyst fluids and in pleural fluid specimens from 19 patients with pleural metastases of various carcinomas (n = 15) or infectious pleurisy (n = 4). PP10 was found in 9 out of 18 follicular or luteal cyst fluids (range 2.0-42.0 micrograms/l) and in 24 out of 29 benign ovarian tumours (range 2.6-38.0 micrograms/l). Nine out of ten malignant ovarian cyst fluids contained detectable PP10 (range 4.0-55.2 micrograms/l). PP10 was found in all the pleural fluids from 15 patients with metastatic bronchial, pulmonary, breast or pancreatic carcinomas (range 5.1-100.2 micrograms/l), as well as from four patients with pleurisy (range 5.0-28.6 micrograms/l). Our results indicate that PP10 is tumour-associated, but not tumour-specific.
Female↗
[Infections complicating pregnancy and delivery, their diagnosis and treatment].
Explore the source record for details and available documents.
Female↗
Endometrial adenocarcinoma: clinical outcome in 881 patients and analysis of 146 patients whose deaths were due to endometrial cancer.
Throughout 1970-1975, 881 patients were treated at Departments I and II of Obstetrics and Gynecology, Helsinki University Central Hospital. They were treated mainly by using surgery and/or radiotherapy combined with adjuvant progestin therapy. The over-all uncorrected 5-year survival rate was 72.2% and corrected rate was 82.1%. In 146 out of 245 cases death was due to endometrial cancer, and this group was analyzed separately.
Adenocarcinoma↗
The content and immunohistochemical localization of placental protein 10 (PP10) in the fallopian tube.
Radioimmunoassay, gel filtration and immunoperoxidase staining were used to study the content and localization of placental protein 10 (PP10) in 15 fallopian tubes removed on medical grounds from patients aged between 35 and 53 years. PP10 was consistently present in all parts of the tube at all ages and in all phases of the menstrual cycle. The PP10 concentration in tissue ranged from 0.08 to 2.95 micrograms/g of tubal cytosol protein. Immunoperoxidase staining localized PP10 in monocytic and lymphoid cells that were unevenly scattered in the subepithelial layer of the mucosa. In gel filtration, PP10 from the fallopian tube and purified placental PP10 eluted in the same volume, and graded amounts of PP10-immunoreactive material from the tube and purified PP10 gave parallel dose-response curves in radioimmunoassay. We conclude that PP10 is another 'placental protein' that has been identified in the fallopian tube.
Adult↗
Human term placenta releases placental protein 10 (PP10) in tissue culture.
Placenta, decidua, chorion and amnion were studied to determine the tissue concentration of placental protein 10 (PP10). As measured by radio-immunoassay, all tissues studied were found to contain approximately the same concentration of PP10, in both early and late pregnancy. The release of PP10 was studied in tissue culture, first by using explants of placenta, decidua, amnion and chorion in four preliminary studies. Only the placenta released significant amounts of PP10 into the culture medium and, therefore, further studies were carried out with placental explants. In gel filtration, the bulk of PP10 in the culture medium eluted in the same position as purified PP10, and the dose-response curves of the two materials were parallel. The total secretion of PP10 into the culture medium was studied throughout 96 hours of incubation. Cycloheximide, a protein synthesis inhibitor, reduced the release of PP10 into medium by 31.3 +/- 12.5%. In cycloheximide-treated tissue cultures, the secretion of PP10 recovered when cycloheximide was replaced by original culture medium without cycloheximide. There results show that placenta is a major source of PP10.
Amnion↗
Circulating levels of placental protein 10 (PP10) in diabetic pregnancy.
Circulating levels of placental protein 10 (PP10) were measured in 217 heparinized plasma samples from 35 insulin-dependent diabetic patients and 90 samples from apparently healthy pregnant women between 15 and 40 weeks. In diabetic pregnancy between 15 and 40 weeks, the levels were significantly below normal (p less than 0.001). Decreased PP10 levels were seen especially in those cases where diabetic pregnancy was complicated by intra-uterine growth retardation, intra-uterine death, or severe congenital malformation. In 9 healthy pregnant women the PP10 levels were measured both in heparinized plasma and in serum samples. The plasma values were 76% of those in serum, suggesting interaction between PP10 and heparin.
Diabetes Mellitus, Type 1↗
Placental protein 10 (PP10) in normal pregnancy and cholestasis of pregnancy.
The circulating concentrations of placental protein 10 (PP10) were measured by radioimmunoassay in 288 women with normal pregnancy and ten women (55 samples) with cholestasis of pregnancy. Serum PP10 levels were not affected by changes in incubation and storage temperature, and no diurnal variation was observed. The highest PP10 levels (36-85 micrograms/l) in normal pregnancy were found at 34 weeks. The postpartum decline of serum PP10 concentration corresponded to an average half-life of 18 h. In cholestasis of pregnancy at 32-39 weeks, the serum PP10 levels were found to be lower than normal. Negative correlation was observed between aminotransferase and PP10 levels in serum and between the bile acid levels and the PP10 concentration. These results suggest that the severity of maternal liver disorder is reflected in the circulating PP10 concentration.
Bile Acids and Salts↗